Decade of Hormone Therapy Reduces Breast Cancer Recurrence

by Julia Samuel on  June 6, 2016 at 8:36 PM Women Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

When the duration of hormone therapy for women with early-stage breast cancer is doubled from five to 10 years, it reduces the risk of recurrence and developing tumors in the other breast, a study shows.
Decade of Hormone Therapy Reduces Breast Cancer Recurrence
Decade of Hormone Therapy Reduces Breast Cancer Recurrence

The study focused on a type of early-stage breast cancer known as hormone receptor-positive. Letrozole is an aromatase inhibitor, which stops estrogen production in postmenopausal women.

The data suggests that "longer durations of widely-available therapy reduce the risk of cancer recurrence, and prevent second cancers from arising," said Harold Burstein, a breast cancer expert and associate professor of medicine at Harvard Medical School not linked to the study.

Lead study author Paul Goss, director of breast cancer research at Boston's Massachusetts General Hospital, said women with early stage hormone-receptor positive breast cancer face an "indefinite risk of relapse."

The study involved 1,918 postmenopausal women in Canada and the United States who had received five years of any one of three aromatase inhibitor therapies either as initial treatment or after taking tamoxifen, another anti-estrogen drug dating back to the 1970s.

Half of the participants received letrozole after a random selection process, while the other half received a placebo.

After a follow-up period of a little more than six years, just seven percent of participants in the letrozole group saw a recurrence of cancer or a tumor in the other breast, compared to 10.2 percent in the control group.

But only 1.4 percent of the women on letrozole developed a cancer in the breast that had been spared, compared to 3.2 percent of those on the placebo.

As concerns recurrence of the initial cancer -- most frequently in the bones, liver or other organs -- the difference between the two groups was smaller -- 5.7 percent in the letrozole group versus 7.1 percent in the control group.

At five years of follow-up, 95 percent of the women receiving letrozole were free of breast cancer, compared to 91 percent in the control group.

Ninety-four percent of the women taking letrozole had survived at the five-year mark, compared to 93 percent of those taking a placebo.

In 2012, more than six million women around the world survived for at least five years after being diagnosed with breast cancer, according to statistics cited by ASCO.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Reiki and Pranic Healing Breast Cancer Facts Cancer Facts Cancer Tattoos A Body Art 

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive